Skip to main content

HARMONi-7 Clinical Study

Harmoni 7

Have you or someone you love been diagnosed with metastatic PD-L1 high non-small cell lung cancer (NSCLC) that has never been treated?

If so, there is a phase 3 clinical study called HARMONi-7 that you may want to ask your doctor about.

HARMONi-7 is a randomized, double-blinded, global Phase 3 study of ivonescimab versus pembrolizumab for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have high PD-L1 levels.


Find a HARMONi-7 Clinical Study Site Near You and Participation Criteria (opens in new window)

For additional information on clinical studies,
contact your doctor or submit a Medical Information Form

What is the purpose of this clinical study?

The purpose of this phase 3 clinical study is to measure overall survival (OS), progression free survival (PFS), and safety of ivonescimab compared to pembrolizumab for the treatment of NSCLC that has spread.

What is the clinical study drug, ivonescimab?

Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body to decrease the cancer cells’ ability to live, grow, and spread.

Your Doctor can provide you with additional information but here are a few things to know:

  • If you are eligible, what is involved? Once enrolled in the clinical study, you will visit the clinic every three weeks for infusions, where the drug is delivered directly to your bloodstream.
  • You will receive regular blood tests and scans of your tumor.
  • You will be regularly asked about any side effects or safety concerns you have, including worsening lung cancer symptoms.

If you are in the clinical study, will you receive ivonescimab?

  • You will be randomly assigned to one of two treatment groups.
  • Half the patients will be assigned to receive ivonescimab and the other half will receive pembrolizumab.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

For additional information on clinical studies,
contact your doctor or submit a Medical Information Form

Download HARMONi-7 Patient Brochure (opens in new window)
Link to ClinicalTrials.gov NCT06767514 (opens in new window)
Sign Up for Updates

For further information on how we protect your information, please refer to our Privacy Policy.

*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

© Summit Therapeutics Inc.

Trademarks, Registered or Otherwise, are the property of their respective owner(s).